Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corp (Nasdaq: OPRX) announced that its Senior VP of Corporate Finance, Andy D'Silva, will participate in the 34th Annual ROTH Conference from March 13-15, 2022, in Dana Point, CA. D'Silva will engage in one-on-one and small group meetings with investors on March 14-15. The conference includes discussions on various growth sectors, featuring approximately 400 companies. OptimizeRx connects over 60% of U.S. healthcare providers, facilitating patient engagement and therapy adherence through its technology platform.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 24% increase in Q4 2021 revenues, reaching $20.3 million, with a gross profit margin of 61%. Full-year revenue rose 42% to $61.3 million. The company achieved a net income of $0.6 million in Q4, down from $1.4 million in the previous year, while non-GAAP net income improved to $4.0 million. The firm anticipates 2022 revenue between $80 million and $85 million, reflecting growth between 31% and 39%.
OptimizeRx Corp (Nasdaq: OPRX) reported preliminary financial results for Q4 2021, anticipating revenues of approximately $20.3 million, marking a 42% increase year-over-year. The company achieved a GAAP net income of $0.6 million and a record adjusted EBITDA of $4.0 million. As part of its growth strategy, OptimizeRx introduced new KPIs focused on customer penetration within the top pharmaceutical manufacturers and aims for 2022 revenues between $80 million to $85 million, projecting 31% to 39% growth.
OptimizeRx Corp. (Nasdaq: OPRX) will conduct a conference call on February 24, 2022, at 4:30 p.m. ET to discuss its fourth-quarter and full-year financial results for 2021. The call will include a Q&A session following the management's presentation. Interested parties can access the conference via toll-free and international numbers or through a webcast link. A replay will be available for 12 months on the OptimizeRx investor website. The Company focuses on digital health solutions, connecting over 60% of U.S. healthcare providers and millions of patients.
OptimizeRx Corp (Nasdaq: OPRX) announced that CEO Will Febbo will participate in Bank of America's Annual HCIT and Digital Health Conference on February 23, 2022. He will speak on a panel titled 'Tech-Enabled Rx Solutions' from 11:15 AM ET to 12:00 PM ET. The event will attract healthcare executives and investors focused on digital health and technology solutions.
OptimizeRx is a leader in point-of-care technology, connecting over 60% of U.S. healthcare providers and millions of patients to improve therapy adherence.
OptimizeRx Corp (Nasdaq: OPRX) announced that vice president of data product, Mike Rousselle, has been named to MM+M’s 40 Under 40 List, highlighting his significant contributions to healthcare marketing. Rousselle is known for leveraging AI and ML to enhance patient-physician communication through the utilization of real-world data. This recognition not only reflects Rousselle's innovative leadership but also reinforces OptimizeRx's commitment to improving patient outcomes by connecting life sciences organizations with healthcare providers effectively.
OptimizeRx Corp (Nasdaq: OPRX), a leading health technology provider, announced participation in two key conferences: the 11th Annual SVB Leerink Global Healthcare Conference on February 17 and the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15. Will Febbo, CEO, will feature in a fireside chat at the SVB event, while the company will present at the BTIG conference. The leadership team will also be available for virtual one-on-one meetings to discuss their innovative point-of-care technology solutions.
OptimizeRx Corp (Nasdaq: OPRX) announced its CEO, Will Febbo, will moderate a panel on 'Telehealth & Digital Medicine: At a Crossroads of Virtual Care' at the LifeSci Partners Corporate Access Event from January 5-7, 2022. The panel will occur on January 6, 2022, at 8:30 AM ET. Other companies participating include Augmedix, DarioHealth, and LifeMD. Interested viewers must register in advance to access the panel. OptimizeRx's technology solutions aim to help patients start and stay on therapy, connecting over 60% of U.S. healthcare providers.
FAQ
What is the current stock price of Optimizerx (OPRX)?
What is the market cap of Optimizerx (OPRX)?
